| abstract |
Use of a transmembrane activator and calcium modulator fusion protein and a cyclophilin ligand interactor (TACI) and an immunoglobulin to provide a drug for inhibiting tumor cell proliferation, wherein the TACI-immunoglobulin fusion protein comprises: (a) a residue of TACI receptors consisting of from the group consisting of: i) amino acid residues 34-104 in Sequence ID No.:2;ii) amino acid residues 30-110 in Sequence ID No.:2; or, iii) amino acid residues 30-154 in Sequence ID No: 2. wherein the TACI receptor residue binds to at least one of ZTNF2 or ZTNF4; and (b) an immunoglobulin residue comprising an immunoglobulin constant region. The application comprises a further 54 claims. |